These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17082012)

  • 41. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
    Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
    Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
    Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
    Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.
    Eichhorst BF; Busch R; Obwandner T; Kuhn-Hallek I; Herschbach P; Hallek M;
    J Clin Oncol; 2007 May; 25(13):1722-31. PubMed ID: 17389338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.
    Malagola M; Damiani D; Martinelli G; Michelutti A; Cesana B; Vivo AD; Piccaluga PP; Ottaviani E; Candoni A; Geromin A; Tiribelli M; Fanin R; Testoni N; Lauria F; Bocchia M; Gobbi M; Pierri I; Zaccaria A; Zuffa E; Mazza P; Priccolo G; Gugliotta L; Bonini A; Visani G; Skert C; Bergonzi C; Roccaro AM; Filí C; Baccarani M; Russo D
    Br J Haematol; 2007 Jan; 136(1):87-95. PubMed ID: 17222198
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.
    Buccisano F; Maurillo L; Tamburini A; Del Poeta G; Del Principe MI; Ammatuna E; Consalvo MI; Campagna S; Ottaviani L; Sarlo C; Renzi D; Faccia S; Fraboni D; Lo Coco F; Amadori S; Venditti A
    Eur J Haematol; 2008 Feb; 80(2):107-14. PubMed ID: 18028430
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
    Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide].
    Nikitin EA; Stadnik EA; Lorie IuIu; Biderman BV; Tsyba NN; Salogub GN; Kolosheĭnova TI; Kolosova LIu; Risinskaia NA; Zaritskiĭ IuA; Kovaleva LG; Sudarikov AB
    Ter Arkh; 2007; 79(7):66-70. PubMed ID: 17802794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early-onset therapy-related myelodysplastic syndrome originating from prolonged myelosuppression after fludarabine-based therapy.
    Yamazaki S; Nakamura F; Nannya Y; Nakagawa M; Ichikawa M; Kurokawa M
    Intern Med; 2012; 51(24):3427-30. PubMed ID: 23257533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
    Swolin B; Rödjer S; Westin J
    Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Secondary myelodysplasia and leukemia following carboplatin and paclitaxel-containing chemotherapy for ovarian cancer].
    Abe A; Ikawa H; Muguruma H; Maeda Y
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1795-8. PubMed ID: 18931592
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
    J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients.
    Niparuck P; Kanoksil W; Chuncharunee S; Boonsakan P; Ungkanont A; Angchaisuksiri P; Karntisaviwat K; Apilugsanachit A; Rerkamnuatchoke B; Jootar S; Nitiyanant P; Atichartakarn V
    Leuk Lymphoma; 2010 Nov; 51(11):2120-5. PubMed ID: 20846095
    [No Abstract]   [Full Text] [Related]  

  • 53. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
    J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
    Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
    Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients.
    Gill S; Lane SW; Crawford J; Cull G; Joske D; Marlton P; Mollee PN; Prince HM; Seymour JF
    Ann Hematol; 2008 Sep; 87(9):727-34. PubMed ID: 18401583
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fludarabine in lymphoproliferative malignancies: a single-centre experience.
    Prabhash K; Vikram GS; Nair R; Sengar M; Gujral S; Bakshi A; Gupta S; Parikh PM
    Natl Med J India; 2008; 21(4):171-4. PubMed ID: 19267037
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximab.
    Martin-Salces M; Canales MA; de Paz R; Hernandez-Navarro F
    Leuk Res; 2008 Jan; 32(1):199-200. PubMed ID: 17870157
    [No Abstract]   [Full Text] [Related]  

  • 58. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
    Rizzieri DA; O'Brien JA; Broadwater G; Decastro CM; Dev P; Diehl L; Beaven A; Lagoo A; Gockerman JP; Chao NJ; Moore JO
    Cancer; 2009 Jul; 115(13):2922-9. PubMed ID: 19452542
    [TBL] [Abstract][Full Text] [Related]  

  • 59. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
    Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
    Deininger MW; Cortes J; Paquette R; Park B; Hochhaus A; Baccarani M; Stone R; Fischer T; Kantarjian H; Niederwieser D; Gambacorti-Passerini C; So C; Gathmann I; Goldman JM; Smith D; Druker BJ; Guilhot F
    Cancer; 2007 Oct; 110(7):1509-19. PubMed ID: 17702093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.